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Objectives: Adenoid cystic carcinoma (ACC) is a locally aggressive salivary gland malignancy prone to perineural invasion
and local recurrences. In the literature, few data exist to guide treatment when this tumor involves the paranasal sinuses and
skull base. We report our experience in the management of sinonasal adenoid cystic carcinoma through an endoscopic endona-
sal approach.
Methods: Retrospective analysis of patients affected by sinonasal ACC treated through an endoscopic endonasal approach
from 1997 to 2015, managed at the Universities of Varese and Brescia, Italy.
Results: Thirty-four patients were included in the analysis. The ethmoid sinus (55.9%), nasal septum (17.7%), maxillary
sinus (11.7%), and sphenoid sinus (5.9%) were the primary tumor sites encountered. Twenty patients (58.8%) presented with
T3 or T4, without any systemic spreading. Twenty-nine patients underwent endoscopic transnasal resection, whereas the
involvement of the anterior skull base in five cases required a transnasal endoscopic craniectomy. Overall, 20 of 34 (58.8%)
patients received some form of adjuvant radiotherapy. The follow-up ranged from 12 to 202 months (mean of 73.2 months).
The 5-year overall, disease-specific, and recurrence-free survival rates were 86.5% ± 7.39%, 86.5% ± 7.39%, and
71.8% ± 8.67%, respectively.
Conclusions: The endoscopic approach is safe and effective for selected sinonasal ACC, reducing the comorbidities of the
external approaches while producing similar oncological results. High T-stage, grade III histology, positive surgical margins,
and perineural infiltration all have an important negative prognostic value.
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INTRODUCTION
Sinonasal cancers account for approximately 4% of
all head and neck malignancies.1–3 Adenoid cystic carci-
nomas (ACC) account for 5% of all sinonasal
malignancies.4,5
ACC is the most common salivary gland tumor and
presents different histological growth patterns (solid,
tubular, and cribriform), which are related with progno-
sis.6 The biological behavior of ACCs is unique. These
tumors have a propensity for perineural spreading
through the skull base, cavernous sinus, and orbit. Long-
term survival is poor, with most patients dying of local
recurrence rather than from distant metastases.7,8 These
features make the surgical management particularly
challenging, and the treatment of ACCs is currently a
matter of debate.
The endoscopic endonasal technique permits a safe
and feasible removal in selected cases, with promising
oncologic outcomes and lower morbidity than with the
external approaches.9 Moreover, adjuvant treatments can
be associated to improve survival and reduce the risk of
recurrences.10
The aim of this study was to analyze the clinical fea-
tures, surgical treatment, and the survival outcomes in
patients affected by ACC and treated endoscopically.
MATERIALS AND METHODS
Patient Population
A retrospective review of patients affected by sinonasal
ACC and treated at the otorhinolaryngology department of the
Universities of Insubria and Brescia between June 1997 and
December 2015 was performed. Institutional review board
approval was obtained.
The patients included were affected by sinonasal and naso-
pharyngeal ACCs treated with radical intent through an endo-
scopic approach. Exclusion criteria were the external approaches,
unresectable disease (involvement of cavernous sinus, internal
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carotid artery, optic nerve, orbital apex, brain, clivus), and endo-
scopic debulking for relief of symptoms.
Epidemiological and clinical data, surgical reports, radiol-
ogy, complications, adjuvant therapies, and follow-up informa-
tion were reviewed. All patients received a preoperative
computed tomography (CT) and magnetic resonance imaging
with gadolinium to evaluate the tumor extension (brain inva-
sion, perineural spread, and to differentiate between inflamma-
tory and neoplastic tissues). Multiple biopsies under endoscopic
control were performed. All patients completed their preopera-
tive staging with a total-body CT scan with enhancement and a
neck ultrasound. The patients included were retrospectively
staged according to the 2010 UICC TNM staging system (7th
Edition).11
Surgery
All patients were informed about the possibility of switch-
ing intraoperatively to a combined cranioendoscopic resection.
The surgical procedures were tailored to the extension of the
tumor together with the patients’ general health and comorbid-
ity. The resection was limited to the sinonasal complex (endo-
scopic endonasal resection) for initial stage tumors. In the case of
involvement of the anterior skull base, the resection was
extended to include the ethmoidal roof and the dura mater of the
anterior skull base from the posterior wall of the frontal sinus to
the planum sphenoidalis and between the medial orbital walls
(endoscopic resection with transnasal craniectomy [ERTC]). In
such cases, transnasal skull base reconstruction was performed
according to a multilayer technique, using autologous materials
(fascia lata or iliotibial tract). Endoscopic nasopharyngectomy
was indicated in the case of infiltration of the nasopharynx.12
When the tumor was extended to the pterygopalatine fossa
(PPF) or the medial wall of the maxillary sinus, the surgery
included the resection of the PPF content or an endoscopic maxil-
lectomy, respectively. In all cases, the surgical margins were
examined intraoperatively with frozen sections, and the re-
section was enlarged until clear margins were obtained or if fur-
ther resections were impossible to achieve regardless of the
approach. The indications, contraindications, and specific surgi-
cal techniques of the different approaches have been detailed
previously.13–15
Postoperative treatments included adjuvant radiotherapy
(RT) in cases of close or positive surgical margins; perineural
invasion or involvement of critical regions such as frontal sinus,
sphenoid sinus, lamina papyracea or periorbit; pterygopalatine
fossa; and anterior skull base (with or without dural infiltration).
The postoperative RT was delivered using the three-dimensional
conformal RT or intensity modulated RT (IMRT) or particle
RT. The clinical target volume usually consisted in the whole re-
section cavity and involved subsites and the possible pathways of
spreading.
Follow-up
Life-long follow-up is necessary. In our cohort, postopera-
tive follow-up was performed with nasal endoscopy every 15 days
until the complete healing of the surgical cavity; then, every
month during the first year, every 4 months during the second
year, and every 6 months thereafter. Postoperative magnetic res-
onance (MR) with gadolinium was performed after 4 months
after surgery and thereafter every 6 months. A systemic staging
with total-body CT scan was performed once a year. No patients
were lost during the follow-up.
Histopathology
Pathological slides were revised independently by two expe-
rienced pathologists and were classified according to Perzin grad-
ing system.6 It foresaw three grades: I was a predominantly
tubular pattern without solid component, II was a predominantly
cribriform pattern with a maximum 30% of solid pattern, and III
was more than 30% of solid pattern.
The revision of the surgical resection specimens also evalu-
ated the perineural, bony, dural, orbital, and brain invasion to
confirm the stage (UICC 2010 TNM staging system 7th
Edition).11
Statistical Analysis
All data were collected and processed with a commercially
available computer software package (SPSS for Windows, version
19; IBM Corp., Armonk, NY). The estimated distribution of the
overall survival (OS), disease-specific survival (DSS), and RFS




A total of 34 patients fulfilled the inclusion criteria.
The clinical and epidemiological data are summarized in
Table I. No gender prevalence was found, and the average
age was 56.8 years old (18–94).
The most reported symptoms were unilateral nasal
obstruction (66%), epistaxis (40%), and headache (30%).
Only two patients were asymptomatic.
Eight patients (24%) referred to our departments
after previous treatments: one patient had RT; three
patients had surgery plus RT; and four patients had
surgery.
The tumors originated from the nasal cavity and eth-
moid in 28 cases (6 T1, 3 T2, 6 T3, 4 T4a, and 9 T4b),
from the maxillary sinus in four cases (3 T1 and 1 T2 for
the extension to the ethmoid), and from the nasopharynx
in two cases staged as T2 and T4. Only a T2 tumor of the
maxillary sinus was N1 at the time of the initial
diagnosis.
The Perzin grade II was the most reported (23 cases,
67.6%), followed by grade III (7 cases, 20.6%) and grade I
(4 cases, 11.8%).
Treatment, Perioperative Outcomes, and
Complications
Twenty-nine patients underwent ER, and in five
cases an ERTC was performed due to the involvement
of the anterior skull base. When the maxillary sinus
was involved (only T1 and T2 were included), we per-
formed an endoscopic medial maxillectomy. The two
patients presenting involvement of the nasopharynx
underwent endoscopic nasopharyngectomy type II
(T2) and type III (T4). There were no major periopera-
tive complications.
Seven patients (20.6%) had positive surgical margins
on histological examination (R1) of the operative speci-
men in sites not amenable for further surgical
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resection (4 cases on the Vidian nerve and 3 on maxillary
nerve).
A postoperative RT was performed in 20 patients
(58.8%) due to advanced-stage disease and close or posi-
tive surgical margins, whereas 14 patients did not require
RT because of early-stage disease and free-margins
resection. The only patient with N1 stage underwent neck
dissection.
The mean follow-up was 73.2 months. At the time of
this study, 25 patients (73.5%) were free from disease
(NED); five patients (14.7%) had died of disease (DOD);
and four patients (11.8%) were alive with disease (AWD).
Ten patients (29.4%) developed recurrence, with a
mean time to recurrence of 44.7 months (range 8–128).
These patients were staged primary tumor (pT)1 (R0) in
one case, pT2 (R0) in two cases, pT3 (R0) in one case,
pT4a (R0 and R1) in two cases, and pT4b in four cases
(3 cases R0 and 1 R1).
Six recurrences were intracranial. Seven of 10 devel-
oped only a local recurrence, three of 10 also developed
distant metastases (two lung metasteses and one lung
and liver metastases), but no patients had regional
metastasis. Two of these 10 patients were NED, four were
AWD, and four were DOD.
Oncological Outcomes
In our cohort, the 5-year OS and the DSS rates were
both 86.5% ± 7.39%, whereas the 10-year OS and DSS were
both 66.8% ± 1.37% (Fig. 1A–Fig. 1B). Overall survival and
DSS data are equal because there are no patients who had
died from other causes, and five patients were DOD. The
5-year OS and DSS depending on surgical margins were
both 93.7% ± 6.05% for the free-margins resection versus
41.7% ± 3.04% for positive margins (P = 0.0144) (Fig. 2A–
Fig. 2B). In addition, the perineural infiltration was ana-
lyzed and we found that it is related with a long-term failure
because the 5-year OS and DSS are similar (87.7% ± 8.2%
without perineural infiltration; 88.9% ± 1.05% for patients
with perineural infiltration). Conversely, the 10-year OS and
DSS were lower for the group with perineural infiltration
(75.2% ± 1.36% vs. 44.4% ± 3.19%, respectively). Neverthe-
less, the Kaplan-Meier curves were not statistically different
(P = 0.144) (Fig. 2C–Fig. 2D).
The 5-year OS and DSS depending on treatment
were both 88.9% ± 1.05 for surgery plus RT versus
84.8% ± 0.09 for surgery alone. On the other hand, the
10-year OS and DSS were 88.9% ± 1.05% for surgery plus
RT versus 58.2% ± 1.72% for surgery alone (P = 0.056)
(Fig. 3D–Fig. 3E) and was close to statistical significance.
TABLE I.




Median age, y 56.8 (18–94) 34
Gender Male 15 (44.1)
Female 19 (55.9)
Disease presentation Initial 26 (76.5)
Recurrent 8 (23.5)
Tumor epicenter Ethmoid sinus 19 (55.9)
Nasal septum 6 (17.7)
Maxillary sinus 4 (11.7)






Grade I 4 (11.8)
Grade II 23 (67.6)
Grade III 7 (20.6)
Treatment Surgery 14 (41.2)
Surgery + RT 20 (57.8)




N classification N0 33 (97.1%)
N+ 1 (2.9)
Distant metastasis M0 34 (100%)
M1 0
Surgical margins Positive 7 (20.6)
Negative 27 (79.4)
Perineural invasion Present 11 (32.3)
Absent 23 (67.7)
Follow-up (months) Range 12–202
N = node; RT = radiotherapy; T = tumor.
Fig. 1. Overall (A), disease-specific (B), and recurrence-free (C) survival of the included population. [Color figure can be viewed in the online
issue, which is available at www.laryngoscope.com.]
Laryngoscope 129: May 2019 Volpi et al.: Sinonasal Adenoid Cystic Carcinoma
1073
Five-year recurrence-free survival (RFS) was
71.8% ± 8.67% due to the occurrence of a local relapse in
10 patients (Fig. 1C). We analyzed the RFS comparing
the T-stage of the tumor and the treatment. It is evident
that recurrences are related with the stage, with a 5-year
RFS of 83.3% ± 1.52% for T1, 75% ± 2.17% for T2, 50% ±
3.54% for T3, 66.7% ± 2.72% for T4a, and 62.3% ± 1.98%
for T4b (P = 0.83) (Fig. 4).
Fig. 2. Overall and disease-specific survival depending on the surgical margins (A–B) and according on the perineural invasion (C–D). [Color
figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
Fig. 3. Overall, disease-specific and recurrence-free survival depending on Perzin grade (A–B–C) and according on the treatment (D–E–F).
[Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
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Five-year RFS depending on treatment were
66.7% ± 1.39% for the surgery alone and 75.2% ± 1.29%
for surgery plus RT (P = 0.04) (Fig. 3F).
Analysis of the 5-year OS and DSS according to the
Perzin grading system (Fig. 3A–Fig. 3B) resulted in 100%
for grade I, 92.9% ± 0.68% for grade II, and
55.6% ± 0.24% for grade III (P = 0.035). The 5-year RFS
depending on the Perzin grading system was 100% for
grade I, 68% ± 1.23% for grade II, and 41.7% ± 3.04% for
grade III (P = 0.041) (Fig. 3C).
DISCUSSION
An ACC is a slow-growing tumor with a propensity
for perineural spreading and intracranial extension.16–18
A free-margin surgical resection is difficult to achieve in
the sinonasal-nasopharyngeal tract because of the critical
relationship with vital structures, the presence of cranial
nerves, and the initial asymptomatic course of the dis-
ease19; therefore, prognosis of ACC of the sinonasal tract
is poor.20 The clinical behavior of ACC can be considered
a paradox: the tumor growth is slow; however, its clinical
course is relentless; multiple local recurrences are the
rule; and the metastatic spreading to regional lymph
nodes is uncommon, although distant spread to the lungs
and bones is frequent. Finally, the 5-year survival rates
are high, but 10- to 20-year survival rates are dramati-
cally low.21
ACC is traditionally classified into three different
subtypes: tubular, cribriform, and solid—with the last
one being related with the worst prognosis. However, in
most of the cases the three different patterns coexist. Per-
zin et al.6 in 1978 proposed a histopathological classifica-
tion dividing ACCs according to the prevalence of the
three different patterns: predominance of tubular compo-
nent without a solid part is classified as grade I; predomi-
nance of cribriform pattern with at least 30% of solid
pattern is classified as grade II; and more than 30% of
solid pattern is classified as grade III. In our analysis, the
worst prognoses and RFS were found for grade III tumors
when compared with grade I through II. Grade III ACC
should be considered as a high-grade tumor due to its
more aggressive growth pattern and tendency for early
development of distant metastases,22–25 and it should be
viewed as a specific entity within the group of ACCs.
Regarding the survival rates, the 5-year OS reported
in the literature for the patients affected by sinonasal
ACC is between 86% and 50%.26 In our study, 5-year and
10-year OS were 86.5% and 66.8%, respectively.
Surgery with or without adjuvant RT is the most
common treatment modality, and the ideal treatment
paradigm has yet to be defined. 27 An extensive preopera-
tive radiological study with a CT scan and MR permits
defining the limits of the tumor and deciding between a
craniofacial resection and an endoscopic approach. These
approaches are not in contrast with each other but pre-
sent different indications for achieving a free-margin
resection. Endoscopic transnasal resection of sinonasal
malignancies has been demonstrated to preserve the
quality of life with oncological results similar to those
achieved with external approaches.28 The absence of
facial incisions and osteotomies, the visualization of
tumor borders, less postoperative pain, shorter hospitali-
zation time, better quality of life, and reduced intraopera-
tive mortality are the major advantages promoting the
endoscopic approach as a good alternative to the tradi-
tional external procedures.29 However, when major ves-
sels need to be crossed or a free-margin resection cannot
be achieved, a combined endoscopic-craniofacial approach
must be planned.
The goal of surgery is a free-margin resection, even
if it is critical due to the submucosal–subperiosteal diffu-
sion and perineural spreading, making intraoperative fro-
zen sections on the resection margins mandatory. In
particular, a radical resection is difficult when the tumor
involves the pterygopalatine fossa, infratemporal fossa,
and superior parapharyngeal space, where it runs along
the nerves into the intracranial space. In our analysis, a
microscopic negative margin demonstrated a statistically
significant improvement of OS, in accordance with the
literature.30
Postoperative radiation seems to provide the best
OS, as reported in recent studies.27,31 Miglianico et al.
found a local control rate of 77.8% at 5 years for patients
treated by surgery plus RT against 44% for patients trea-
ted by surgery alone. Lupinetti et al. evidenced a signifi-
cant difference in disease-specific survival (P = 0.05). Our
5-year and 10-year OS rates, depending on treatment
(surgery plus RT vs. surgery), were respectively 88.9%
versus 84.8% (5 year) and 88.9% versus 58.2% (10 year),
confirming the long-term data of the literature. The
majority of authors describe a combination of primary
surgery, followed by adjuvant RT as the recommended
treatment. However, the benefit of adjuvant RT has never
been demonstrated clearly.26 Postoperative radiation may
be delivered using conventional photon RT (e.g., IMRT) or
taking advantage of the recently introduced particle ther-
apy, especially carbon ion therapy, which has shown
promising rates of local control as adjuvant treatment
and also for inoperable cases.32 Ramaekers et al. showed
that the 5-year local control rate after proton therapy is
Fig. 4. Recurrence-free survival depending on T stage. [Color figure
can be viewed in the online issue, which is available at www.laryn
goscope.com.]
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higher than achieved with IMRT for cases of sinonasal
cancer (88% vs. 66%, P = 0.035). The limited data avail-
able indicate that toxicity tends to be lower for carbon-ion
and proton compared to photon RT.33
According to our data, perineural infiltration influ-
ences the survival rates: 10-year OS without infiltration
was 75.2%, whereas 10-year OS with infiltration was
44.4% even if no a clear statistically significant difference
was evident (P = 0.144). According to Garden et al., the
perineural infiltration is in relation not only with the
overall survival but also with local recurrence of the dis-
ease. In that study, Garden et al. showed how patients
either with or without perineural infiltration have failure
rates of 18% and 9%, respectively (P = 0.02).23
Local recurrence rather than distant metastases is
the main event in ACC’s history and develops in a signifi-
cant percentage of patients (65%).27 According to the lit-
erature, advanced stages of disease, perineural invasion,
positive margins of surgical resection, and omission of
postoperative radiation are independent predictors of
local recurrence.26 Our results indicate that histopatho-
logical grade, T stage, and the treatment all influence
local recurrence. Maxillary sinus, sphenoid sinus, and
nasopharynx are associated with a significant percentage
of relapses, probably due to the close relationship with
major nerve (Vidian, V2, V3). Lupinetti et al., in their ret-
rospective review, show how patients with nasal cavity
tumors have the best survival, whereas patients with
sphenoid tumors have the worst survival.27
In contrast to sinonasal squamous cell carcinoma,
lymphatic spreading to the neck plays a minor role in the
spread of ACC. Nodal involvement in this histology with
this location is rare (0–5%).8,34 In our study, only one
patient (1 of 34) showed a regional nodal metastasis at
the time of diagnosis, and no patient developed neck
metastases during follow-up.
Distant metastases at diagnosis are also rare, with
reported rates of 1% to 3%.8,34 The most frequent sites
are lung, bone, liver, and brain. In our study, none of the
patients presented distant metastases at the time of diag-
nosis. However, three patients developed distant metas-
tases during follow-up; one patient had liver and lung
metastases after 16 months and is alive with disease
33 months after surgery. Two patients had lung metasta-
ses; one is alive with disease after 33 months, and the
other was DOD after 61 months.
As reported in literature, the biological behavior of
the primitive cancer as reported in literature permits a
prolonged survival also in metastatic patients, particu-
larly in cases with lungs metastasis.34,35 These findings
explain how the presence of metastases should not
exclude correct treatment of the primary site. At the time
of this study, our data are sufficient for a discussion on
this topic.
CONCLUSION
Our study demonstrates how the prominent issue in
sinonasal ACC is long-term disease control, and the refer-
ence treatment should be surgical resection with clear
margins followed by adjuvant radiotherapy. The
endoscopic approach is safe and effective for selected sino-
nasal ACC, reducing the morbidities of the external
approaches while producing similar oncological results.
High T-stage, grade III histology, positive surgical
margins, and perineural infiltration play an important
role in negative prognosis.
Radiotherapy is crucial in case of positive surgical
margins and perineural spreading, probably delaying the
recurrences. Longer follow-up and larger series are
needed to better evaluate the role of the endoscopic
approach and to understand the biological behavior of
the ACC.
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